SUTRO BIOPHARMA, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
SUTRO BIOPHARMA, INC. (STRO) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $55.19 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $55.19M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $74.54M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $58.99M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $66.78M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $55.19M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $74.54M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $58.99M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $66.78M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $64.88M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $107.09M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $191.16M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $175.44M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $91.64M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $66.08M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $70.14M 10-K · filed 2026-03-23 |
| 2023-09-30 | $82.71M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $235.97M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $63.34M 10-Q · filed 2024-05-13 |
| 2022-12-31 | $48.13M 10-K · filed 2025-03-13 |
| 2022-09-30 | $97.65M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $79.99M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $29.77M 10-Q · filed 2023-05-15 |
| 2021-12-31 | $31.29M 10-K · filed 2025-03-13 |
| 2021-09-30 | $31.58M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $57.26M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $56.69M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $207.02M 10-K · filed 2024-03-25 |
| 2020-09-30 | $65.24M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $65.36M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $43.58M 10-Q · filed 2021-05-07 |
| 2019-12-31 | $4.97M 10-K · filed 2023-03-30 |
| 2019-09-30 | $11.97M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $19.41M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $26.63M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $125.31M 10-K · filed 2022-02-28 |
| 2018-09-30 | $41.37M 10-Q · filed 2019-11-08 |
| 2017-12-31 | $22.04M 10-K · filed 2021-03-18 |
| 2016-12-31 | $11.87M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |